BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15590399)

  • 1. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
    Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ; Mendenhall NP; Hudson JK
    Am J Clin Oncol; 2002 Aug; 25(4):391-7. PubMed ID: 12151972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
    J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
    Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
    J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Magagnoli M; Rondelli D; de Vivo A; Benni M; Zamagni E; Cavo M; Tura S
    Eur J Haematol; 1997 Aug; 59(2):82-8. PubMed ID: 9293855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
    Hochster HS; Kim KM; Green MD; Mann RB; Neiman RS; Oken MM; Cassileth PA; Stott P; Ritch P; O'Connell MJ
    J Clin Oncol; 1992 Jan; 10(1):28-32. PubMed ID: 1727921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
    Hochster HS; Oken MM; Winter JN; Gordon LI; Raphael BG; Bennett JM; Cassileth PA
    J Clin Oncol; 2000 Mar; 18(5):987-94. PubMed ID: 10694548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
    Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
    J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
    Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
    Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
    J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.